NRXP (NRX Pharmaceuticals Inc.) stock: $3.32, $143.7M market cap, $26.7M cash, $117.0M EV, $177.0M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
NRX-100
Stage not disclosed · Active Modality: small molecule (IV infusion formulation)
Target NMDA receptor
Status note Lead candidate; preservative-free formulation of ketamine for IV infusion. No phase or indication stated in excerpts.
KETAFREE
Stage not disclosed · Active Modality: small molecule (generic formulation)
Target NMDA receptor
Status note Generic preservative-free formulation of ketamine. No phase or indication stated in excerpts.
NRX-101
Stage not disclosed · Active Modality: small molecule (oral fixed-dose combination)
Status note Oral fixed-dose combination of D-cycloserine (DCS) and lurasidone. No phase or indication stated in excerpts.
NRX-200
Preclinical · Active Modality: small molecule (subcutaneous formulation)
Status note pH-neutral form of ketamine suitable for subcutaneous administration.
Temelimab
Stage not disclosed · Active Modality: monoclonal antibody
Target HERV-W envelope protein
Partnerships NIH (CRADA + shared patents); Fondation FundaMental of France (shared patents for schizophrenia). Held via GeNeuro, Inc. subsidiary (assets awarded by Swiss courts Jun 2026).
Indications- Multiple sclerosis (MS) (Stage not disclosed)
- Type 1 diabetes (Stage not disclosed)
- Long Covid (Stage not disclosed)
Status note Monoclonal antibody against HERV-W envelope protein (via GeNeuro, Inc.). Studied in MS, Type 1 diabetes, and Long Covid; preclinical work in schizophrenia. No phase stated in excerpts.
GNK-301
Preclinical · Active
Partnerships NIH (developed in partnership). Held via GeNeuro, Inc. subsidiary.
Status note Preclinical asset developed in partnership with NIH (via GeNeuro, Inc.). Studied in ALS models and human brain cell culture.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.